;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • NextCode, University College Dublin deal

    NextCode Health, Cambridge, Mass. University College Dublin, Dublin, Ireland Business: Neurology, Genomics NextCode granted the university a non-exclusive license to the companys Clinical Sequence Analyzer, Sequence …

    Published on 7/21/2014
  • Novartis, ProBioGen deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland ProBioGen AG, Berlin, Germany Business: Antibodies ProBioGen granted Novartis a non-exclusive license to use ProBioGens GlymaxX technology to enhance antibody-…

    Published on 7/21/2014
  • Oasmia deal

    Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Business: Drug delivery Oasmia signed a research deal with an undisclosed pharma to use Oasmias XR-17 nanoparticle formulation technology. Oasmia will perform tests…

    Published on 7/21/2014
  • Pfizer, InnoPharma deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. InnoPharma Inc., Piscataway, N.J. Business: Drug delivery, Generics Pfizer will acquire sterile injectable company InnoPharma for $225 million in cash up front. InnoPharma is also …

    Published on 7/21/2014
  • Roche, Stratos Genomics deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Stratos Genomics Inc., Seattle, Wash. Business: Supply/Service Roche partnered with Stratos Genomics to develop unique chemistry applied to single molecule sequencing of …

    Published on 7/21/2014
  • Shire, AbbVie deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Pharmaceuticals AbbVie will acquire Shire for about L31.4 billion ($53.8 billion) in cash and stock. The offer comprises …

    Published on 7/21/2014
  • SimBioSys, Wiley deal

    SimBioSys Inc., Toronto, Ontario John Wiley & Sons Inc., Hoboken, N.J. Business: Supply/Service Wiley acquired scientific software tools company SimBioSys. SimBioSys uses computer-aided retrosynthetic analysis to …

    Published on 7/21/2014
  • Synthon, Abzena deal

    Synthon B.V., Nijmegen, the Netherlands Abzena Ltd. (LSE:ABZA), London, U.K. Business: Cancer, Antibodies Abzenas Antitope Ltd. subsidiary will use its EpiScreen ex vivo human T cell assay to determine the potential …

    Published on 7/21/2014
  • Tiziana Life Sciences, Italian Foundation for Cancer Research, European Institute of Oncology deal

    Tiziana Life Sciences plc (LSE:TILS), London, U.K. Italian Foundation for Cancer Research, Milan, Italy European Institute of Oncology, Milan, Italy Business: Diagnostic, Pharmacogenetics The Italian Foundation for …

    Published on 7/21/2014
  • Transgenomic, Integrated DNA deal

    Transgenomic Inc. (NASDAQ:TBIO), Omaha, Neb. Integrated DNA Technologies Inc., Coralville, Iowa Business: Functional genomics Transgenomic sold Integrated DNA Technologies (IDT) all of Transgenomics rights, title and …

    Published on 7/21/2014
  • Valeant Pharmaceuticals, PreCision Dermatology deal

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Montreal, Quebec PreCision Dermatology Inc., Cumberland, R.I. Business: Dermatology Valeant completed its acquisition of dermatology company PreCision for $…

    Published on 7/21/2014
  • Zalicus, Epirus deal

    Zalicus Inc., Cambridge, Mass. Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. Business: Autoimmune, Biosimilars Epirus completed its reverse merger with Zalicus, and the combined company, named Epirus …

    Published on 7/21/2014
  • Agenus, Ludwig Cancer Research deal

    Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Ludwig Cancer Research, New York, N.Y. Business: Antibodies, Cancer The partners selected three antibody checkpoint modulators to advance into preclinical development for …

    Published on 3/10/2014
  • Aires, Mast Therapeutics deal

    Aires Pharmaceuticals Inc., San Diego, Calif. Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Business: Cardiovascular, Hematology Mast completed its acquisition of cardiovascular company Aires in a stock deal. …

    Published on 3/10/2014
  • Alchemia, Cancer Research Technology deal

    Alchemia Ltd. (ASX:ACL), Brisbane, Australia Cancer Research Technology Ltd., London, U.K. Business: Cancer Alchemia licensed two preclinical focal adhesion kinase (FAK) inhibitors from Cancer Research Technology. …

    Published on 3/10/2014
  • Alnylam, Merck deal

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Genomics Alnylam completed its acquisition of Merck's Sirna Therapeutics Inc. subsidiary for $…

    Published on 3/10/2014
  • Alnylam, Sanofi deal

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic, Hematology Sanofi's Genzyme Corp. unit completed the purchase of 8.8 million …

    Published on 3/10/2014
  • Amarantus BioScience, University of Massachusetts deal

    Amarantus Bioscience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. University of Massachusetts, Amherst, Mass. Business: Other Amarantus and the university entered an exclusive option agreement to license the …

    Published on 3/10/2014
  • AntaBio, The Wellcome Trust deal

    AntaBio, Labege, France The Wellcome Trust, London, U.K. Business: Infectious AntaBio received a 1.7 million ($2.3 million) milestone payment from The Wellcome Trust under a 2013 deal to develop a small molecule pan-…

    Published on 3/10/2014
  • Arno, University of Minnesota deal

    Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. University of Minnesota, Minneapolis, Minn. Business: Pharmacogenetics The university granted Arno an exclusive, worldwide license to a cancer diagnostic technique, …

    Published on 3/10/2014
  • Bayer, Dihon Pharmaceutical Group deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Dihon Pharmaceutical Group Co. Ltd., Kunming Yunnan, China Business: Pharmaceuticals Bayer will acquire Dihon, which specializes in OTC and herbal traditional Chinese medicine …

    Published on 3/10/2014
  • Biogen Idec, Eisai deal

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Neurology The companies partnered to co-develop and co-commercialize Eisai's E2609 and BAN2401 for Alzheimer's disease. …

    Published on 3/10/2014
  • Biotie Therapeutics Corp., Neurelis deal

    Biotie Therapeutics Corp. (HSE:BTH1V), Turku, Finland Neurelis Inc., Encinitas, Calif. Business: Neurology Biotie provided an update and said it will not exercise its option to acquire Neurelis in a stock deal. Biotie …

    Published on 3/10/2014
  • Cytocell, Oxford Gene deal

    Cytocell Ltd., Cambridge, U.K. Oxford Gene Technology, Oxford, U.K. Business: Diagnostic Oxford Gene Technology acquired Cytocell, which develops and markets fluorescence in situ hybridization (FISH)-based diagnostics …

    Published on 3/10/2014
  • diaDexus, Thermo Fisher deal

    diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Business: Diagnostic Thermo Fisher granted diaDexus exclusive rights to develop and commercialize …

    Published on 3/10/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993